At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 352 enrolled
Drug / intervention
Apremilast 10mg +5 moredrug
Likely dose
Apremilast 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
In Brief
A Phase 2 clinical trial evaluating Apremilast 10mg, Apremilast 20mg, and 3 other interventions for Psoriasis and Plaque-type Psoriasis. Completed, enrolled 352 participants across 35 sites in 2 countries.
Detailed Summary
The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Plaque-type Psoriasis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedOct 2008
Primary CompletionAug 2009
Study CompletionMay 2015
TodayJul 2026
First PostedOct 16, 2008
Enrollment StartSep 1, 2008
Primary CompletionAug 1, 2009
Study CompletionMay 20, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.7 years ago
Interventions
Apremilast 10mgdrug
Apremilast 20mgdrug
Apremilast 30 mgdrug
Placebodrug
Apremilast 30mgdrug
Apremilast 20mgdrug